<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711416045</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711416045</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Risk</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Westerink</surname><given-names>Jan</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711416045">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>van der Graaf</surname><given-names>Yolanda</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711416045">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Faber</surname><given-names>Daniël R</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711416045">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Spiering</surname><given-names>Wilko</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711416045">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Visseren</surname><given-names>Frank LJ</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711416045">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826711416045"/>
</contrib>
<on-behalf-of>(on behalf of the SMART study group)</on-behalf-of>
</contrib-group>
<aff id="aff1-1741826711416045"><label>1</label>University Medical Center Utrecht, Utrecht, The Netherlands.</aff>
<aff id="aff2-1741826711416045"><label>2</label>Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands.</aff>
<author-notes>
<corresp id="corresp1-1741826711416045">Frank LJ Visseren, Department of Vascular Medicine, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands Email: <email>F.L.J.Visseren@umcutrecht.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>4</issue>
<fpage>864</fpage>
<lpage>873</lpage>
<history>
<date date-type="received"><day>14</day><month>1</month><year>2011</year></date>
<date date-type="accepted"><day>15</day><month>6</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Aims:</bold> To investigate whether levels of thyroid-stimulating hormone (TSH) within the normal range are associated with an increased risk of new vascular events and mortality in patients with clinical manifest vascular diseases and whether this relation is influenced by adiposity.</p>
<p><bold>Methods and results:</bold> Prospective cohort study in 2443 patients (1790 men and 653 women) with clinical manifest vascular disease and TSH levels in the normal range. Median follow up was 2.7 (interquartile range 1.4–3.9) years. Clinical endpoints of interest were: myocardial infarction, stroke, vascular death, and all-cause mortality. In patients with manifest vascular disease, the prevalence of (subclinical) hypothyroidism was 5.7%, while 3.6% had (subclinical) hyperthyroidism. An increase in 1 unit of TSH was associated with a 33% higher risk (HR 1.33; 95% CI 1.03–1.73) for the occurrence of myocardial infarction, adjusted for age, gender, renal function, and smoking. In patients with a body mass index (BMI) below the median of 26.7 kg/m<sup>2</sup> the HR per unit TSH for myocardial infarction was 1.55 (95% CI 1.08–2.21) compared to 1.18 (95% CI 0.81–1.71) in patients with a BMI ≥26.7 kg/m<sup>2</sup>. Visceral adipose tissue thickness below the median (≤8.8 cm) was associated with higher HR per unit TSH for myocardial infarction (HR 1.69; 95% CI 1.21–2.35) compared to visceral adipose tissue thickness &gt;8.9 cm (HR 1.00; 95% CI 0.66–1.49). There was no relation between TSH and risk of stroke, vascular death, the combined endpoint, or all-cause mortality.</p>
<p><bold>Conclusion:</bold> Higher TSH levels within the normal range are associated with an increased risk of myocardial infarction, in patients with clinical manifest vascular disease. This relation is most prominent in patients without visceral obesity.</p>
</abstract>
<kwd-group>
<kwd>Adiposity</kwd>
<kwd>thyroid-stimulating hormone</kwd>
<kwd>vascular diseases</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711416045" sec-type="intro"><title>Introduction</title>
<p>The direct effects of triiodothyronine (T3) on the cardiovascular system are manifold and include cardiac inotropism and chronotropism.<sup><xref ref-type="bibr" rid="bibr1-1741826711416045">1</xref></sup> Supplementation of T3 results in an acute reduction in peripheral vascular resistance<sup><xref ref-type="bibr" rid="bibr1-1741826711416045">1</xref>,<xref ref-type="bibr" rid="bibr2-1741826711416045">2</xref></sup> Several studies indicate that overt hypothyroidism is associated with an elevated risk of cardiovascular disease through an increase in lipid levels, hypertension, inflammation, endothelial dysfunction, and a deterioration of cardiac function.<sup><xref ref-type="bibr" rid="bibr3-1741826711416045">3</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr7-1741826711416045">7</xref></sup> Treatment with thyroid hormone in patients with hypothyroidism leads to a decrease in intima media thickness (IMT) probably through lowering of low-density lipoprotein (LDL) cholesterol, although this treatment effect seems to be absent in patients with subclinical hypothyroidism.<sup><xref ref-type="bibr" rid="bibr8-1741826711416045">8</xref>,<xref ref-type="bibr" rid="bibr9-1741826711416045">9</xref></sup></p>
<p>Whether subclinical hypothyroidism is associated with a an increased risk for coronary artery disease and mortality is uncertain and maybe limited to plasma TSH levels above 10 mU/l.<sup><xref ref-type="bibr" rid="bibr10-1741826711416045">10</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr12-1741826711416045">12</xref></sup> The mechanisms through which subclinical hypothyroidism may increase cardiovascular risk include an effect on LDL-cholesterol, inflammation, and endothelial dysfunction.<sup><xref ref-type="bibr" rid="bibr9-1741826711416045">9</xref>,<xref ref-type="bibr" rid="bibr13-1741826711416045">13</xref>,<xref ref-type="bibr" rid="bibr14-1741826711416045">14</xref></sup> Even TSH levels within the normal range were associated with an increased risk for cardiac mortality, although only in women.<sup><xref ref-type="bibr" rid="bibr15-1741826711416045">15</xref></sup> The relation between plasma TSH levels and cardiovascular events may be influenced by their complex relations with adiposity. Adiposity is strongly correlated with plasma TSH levels, while changes in bodyweight are associated with changes in TSH plasma levels.<sup><xref ref-type="bibr" rid="bibr16-1741826711416045">16</xref>,<xref ref-type="bibr" rid="bibr17-1741826711416045">17</xref></sup> While it is conceivable that changes in thyroid function may cause changes in adiposity through its influence on metabolism, adiposity may also influence plasma TSH levels through the effect of leptin on the release of thyroid-releasing hormone.<sup><xref ref-type="bibr" rid="bibr18-1741826711416045">18</xref></sup> In light of this complex relation and the well-established cardiovascular risk associated with obesity,<sup><xref ref-type="bibr" rid="bibr19-1741826711416045">19</xref></sup> adiposity could be part of the causal pathway between TSH and cardiovascular events in several ways.</p>
<p>The aim of the present study was to investigate the prevalence of overt and subclinical thyroid disease in a cohort of patients with various clinical manifestations of vascular disease, to investigate whether TSH levels within the normal range are associated with an increased risk of new vascular events and to investigate whether this relation was influenced by adiposity.</p>
</sec>
<sec id="sec2-1741826711416045" sec-type="methods"><title>Methods</title>
<sec id="sec3-1741826711416045"><title>Study design and patients</title>
<p>For this study, data were used from patients enrolled in the SMART study (Second Manifestations of ARTerial disease), an ongoing single centre prospective cohort study carried out at the University Medical Center Utrecht, the Netherlands. From 1996 on, patients aged between the ages of 18 and 80 years, referred to our centre with clinically manifest atherosclerotic vascular disease (coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm) or with cardiovascular risk factors (hyperlipidaemia, diabetes, or hypertension) are included. Patients were included in the SMART study &gt;6 months after the most recent cardiovascular event. Patients with terminal malignant disease, those not independent in daily activities (Rankin scale &gt;3), or not sufficiently fluent in Dutch were excluded.</p>
<p>The aims of the SMART study are to determine: (i) the risk factors for atherosclerosis, (ii) the prevalence of additional vascular disease, and (iii) the incidence of future cardiovascular events. The Medical Ethics Committee has approved the study and all patients gave written informed consent. Patients were asked to complete a health questionnaire covering medical history, risk factors, current or past smoking habits, and medical treatment. A standardized diagnostic protocol was followed consisting of physical examination and laboratory testing in a fasting state. A more detailed description of the design of the study has been published previously.<sup><xref ref-type="bibr" rid="bibr20-1741826711416045">20</xref></sup></p>
<p>For the current study, only data from the inclusion period July 2003 to February 2009 were used, as TSH levels were measured in consecutive patients as part of the standard diagnostic protocol starting from July 2003. The study population was further restricted by selecting only those patients with manifest vascular disease at inclusion (<italic>n </italic>= 2731). Patients receiving thyroid hormone supplementation or anti-thyroid medication were excluded from analyses (<italic>n </italic>= 82). For data analyses on the relation between TSH levels and new vascular events, patients with missing plasma TSH (<italic>n </italic>= 34), TSH &lt;0.5 mU/l (<italic>n </italic>= 90), or &gt;5.0 mU/l (<italic>n </italic>= 82) were excluded to restrict analyses to TSH plasma levels in the normal range (<italic>n </italic>= 2443) (<xref ref-type="fig" rid="fig1-1741826711416045">Figure 1</xref>).
<fig id="fig1-1741826711416045" position="float"><label>Figure 1.</label><caption><p>Population selection and prevalence of (anti-)thyroid medication use and plasma thyroid-stimulating hormone (TSH) levels outside the normal range.</p></caption><graphic xlink:href="10.1177_1741826711416045-fig1.tif"/></fig></p>
</sec>
<sec id="sec4-1741826711416045"><title>Measurement of TSH</title>
<p>From July 2003 until November 2006, TSH was quantified by a third-generation assay on a Centaur analyser (Bayer, Germany), which had an interassay variation of 0.22 mU/l (6%), 4.5 mU/l (5.5%), 16.5 mU/l (5.2%), and a functional sensitivity of 0.02 mU/l with an interassay imprecision of 20%. From December 2006, TSH was quantified by a third-generation assay on a DXi analyser (Beckman Coulter, Woerden, The Netherlands), which had an interassay variation of 4⊟8% and a functional sensitivity of 0.015 mU/l with an interassay imprecision of 20%. Correlation between the two analysers was <italic>r </italic>= 0.9991 (<italic>n </italic>= 69), with an intercept of ⊟0.05 mU/l (95% CI ⊟0.22 to 0.12) and a slope of 1.04 (95% CI 1.029–1.052) (range 0⊟95 mU/l).</p>
</sec>
<sec id="sec5-1741826711416045"><title>Measurements of adiposity</title>
<p>Body mass index (BMI) was calculated by dividing bodyweight by the square of the body length in meters. Waist circumference was measured halfway between the lowest rib and the iliac crest, taken in standing position. Intra-abdominal fat was measured with B-mode ultrasound, by well-trained registered vascular technicians in a certified radiology department. Ultrasonographic measurements were done in supine position using an ATL HDI 3000 (Philips Medical Systems, Eindhoven, The Netherlands) with a C 4⊟2 transducer. Intra-abdominal fat was ultrasonographically measured as the distance between the peritoneum and the lumbar spine or psoas muscles using electronic callipers. The transducer was placed in a straight line drawn between the left and right midpoints of the lower rib and the iliac crest. Measurements were performed at the end of a quiet inspiration, applying minimal pressure without displacement or compression of the abdominal cavity. The distance was measured three times at three different positions. Previously, the ultrasound protocol for measuring intra-abdominal fat was compared with computed tomography (CT) at our centre.<sup><xref ref-type="bibr" rid="bibr21-1741826711416045">21</xref></sup> Ultrasonographic measurements were strongly associated with CT measurements of intra-abdominal fat: Pearson’s correlation coefficient was 0.81 (<italic>p </italic>&lt; 0.001). Also, an inter-observer coefficient of variation of 5.4% was found for ultrasound measurements of intra-abdominal fat, indicating good reproducibility.</p>
</sec>
<sec id="sec6-1741826711416045"><title>Data analyses</title>
<p>Baseline data are presented as mean±standard deviation or median with interquartile range in the case of a skewed distribution. Baseline characteristics within tertiles of plasma TSH levels within the normal range were compared using one-way ANOVA or Kruskal−Wallis when appropriate. Cox proportional hazard models were built to estimate the hazard ratios (HR) with corresponding 95% confidence intervals (CIs) of TSH for the occurrence of new cardiovascular events in patients with plasma TSH levels within the normal range. Clinical endpoints of interest were: myocardial infarction, stroke, vascular death, total mortality, and the combined endpoint of all vascular events including myocardial infarction, stroke, abdominal aortic aneurysms, and other vascular events. If a patient had multiple events, the first event was taken. The HR denotes the increase in risk for the new cardiovascular event per one mU/l rise in level of TSH. Three models were constructed, the first only including TSH (model I). In model II, additional adjustment was made for age and sex. In model III, adjustment included renal function as measured with the MODIFICATION OF DIET IN RENAL DISEASE (MDRD) and current smoking as both influence cardiovascular risk and plasma TSH levels.<sup><xref ref-type="bibr" rid="bibr22-1741826711416045">22</xref>,<xref ref-type="bibr" rid="bibr23-1741826711416045">23</xref></sup> Exploratory models were created to evaluate the role of beta-blocker use and site of initial vascular disease. As thyroid function might influence blood pressure and plasma lipid levels and could therefore be seen as part of the causal pathway we did not include these factors in the primary analyses. For an exploratory model including total cholesterol, HDL-cholesterol, the use of lipid-lowering agents, systolic blood pressure, and the use of blood pressure-lowering medication we imputed missing values for the following variables: total cholesterol (<italic>n </italic>= 6), HDL cholesterol (<italic>n </italic>= 14), and systolic blood pressure (<italic>n </italic>= 18). We confirmed the proportional hazard assumption of the Cox model by testing the correlations between scaled Schoenfeld residuals for plasma TSH levels and time. We confirmed a linear relation between plasma TSH levels and endpoints by comparing the Akaike Information Criterion of the multivariate-adjusted model containing a linear term for TSH, log-transformed TSH, and TSH squared.</p>
<p>Given the complicated relation between TSH and bodyweight, measures of adiposity could be part of the causal pathway and were therefore not entered in models nor were standard multiplicative interaction analyses performed.<sup><xref ref-type="bibr" rid="bibr16-1741826711416045">16</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr18-1741826711416045">18</xref></sup> Stratification on the median of different measures of adiposity (BMI, waist circumference, and visceral adipose tissue thickness) and standard cut-off values of BMI was performed to assess their potential effect on the determinant-outcome relation. To reduce bias and to improve statistical efficiency, missing values for MDRD (<italic>n </italic>= 8), smoking status (<italic>n </italic>= 3), BMI (<italic>n </italic>= 2), waist circumference (<italic>n </italic>= 82), and visceral adipose tissue (<italic>n </italic>= 7) were completed in the dataset by single regression imputation, leaving 2443 complete datasets for Cox proportional hazard analyses.</p>
</sec>
</sec>
<sec id="sec7-1741826711416045" sec-type="results"><title>Results</title>
<sec id="sec8-1741826711416045"><title>Baseline characteristics and prevalence of thyroid disorders in patients with vascular diseases</title>
<p>In the 2731 patients with clinical manifest vascular disease, the prevalence of (subclinical) hypothyroidism (earlier diagnosis of hypothyroidism (<italic>n </italic>= 74) or TSH &gt;5.0 mU/l (<italic>n </italic>= 82)) was 5.7%, while 3.6% had (subclinical) hyperthyroidism [earlier diagnosis of hyperthyroidism (<italic>n </italic>= 8) or TSH &lt;0.5 mU/l (<italic>n </italic>= 90)]. The baseline characteristics of the patients with TSH levels &lt;0.5 mU/l (<italic>n </italic>= 90), 0.5−5.0 mU/l (<italic>n </italic>= 2443) and &gt;5.0 mU/l (<italic>n </italic>= 82) are presented in <xref ref-type="table" rid="table1-1741826711416045">Table 1</xref>. The proportion of women increased (23%⊟26%⊟31%) while current smoking decreased (36%⊟28%⊟24%) over the tertiles of TSH in the normal range. In the study population 16 patients (0.7%) used either amiodarone or drondarone.
<table-wrap id="table1-1741826711416045" position="float"><label>Table 1.</label><caption><p>Baseline characteristics</p></caption>
<graphic alternate-form-of="table1-1741826711416045" xlink:href="10.1177_1741826711416045-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="4"/><th colspan="5">TSH (mU/l, <italic>n </italic>= 2615)<hr/></th>
<th rowspan="4"><italic>p</italic>-value</th></tr>
<tr><th/>
<th/>
<th colspan="3">Plasma levels in normal range (<italic>n </italic>= 2443)<hr/></th></tr>
<tr><th>&lt;0.5<hr/></th>
<th>&gt;5.0</th>
<th>0.5–1.33 mU/l</th>
<th>1.34–2.05</th>
<th>2.07–5.00</th></tr>
<tr>
<td><italic>n </italic>= 90</td>
<td><italic>n </italic>= 82</td>
<td><italic>n </italic>= 819</td>
<td><italic>n </italic>= 809</td>
<td><italic>n </italic>= 815</td></tr></thead>
<tbody align="left">
<tr>
<td>Male gender</td>
<td>61 (68)</td>
<td>52 (63)</td>
<td>628 (77)</td>
<td>601 (74)</td>
<td>561 (69)</td>
<td>0.001</td></tr>
<tr>
<td>Age (years)</td>
<td>62.0 ± 10.8</td>
<td>62.2 ± 12.2</td>
<td>59.2 ± 10.1</td>
<td>59.1 ± 10.4</td>
<td>60.4 ± 10.1</td>
<td>0.021</td></tr>
<tr>
<td>Smoking, ever</td>
<td>69 (77)</td>
<td>66 (81)</td>
<td>699 (85)</td>
<td>619 (77)</td>
<td>608 (75)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Smoking, current</td>
<td>31 (34)</td>
<td>21 (26)</td>
<td>291 (36)</td>
<td>229 (28)</td>
<td>192 (24)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Blood pressure systolic (mmHg)</td>
<td>142 ± 20</td>
<td>147 ± 23</td>
<td>142 ± 21</td>
<td>141 ± 21</td>
<td>143 ± 22</td>
<td>0.069</td></tr>
<tr>
<td>Blood pressure diastolic (mmHg)</td>
<td>83 ± 12</td>
<td>84 ± 12</td>
<td>83 ± 11</td>
<td>83 ± 11</td>
<td>84 ± 11</td>
<td>0.100</td></tr>
<tr>
<td>TSH (mU/l)</td>
<td>0.31 (0.16–0.40)</td>
<td>6.69 (5.74–8.93)</td>
<td>1.00 (0.83–1.20)</td>
<td>1.65 (1.50–1.82)</td>
<td>2.70 (2.30–3.30)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.35 ± 1.12</td>
<td>4.60 ± 1.15</td>
<td>4.57 ± 1.11</td>
<td>4.54 ± 1.14</td>
<td>4.62 ± 1.20</td>
<td>0.422</td></tr>
<tr>
<td>LDL cholesterol (mmol/l)<sup><xref ref-type="table-fn" rid="table-fn2-1741826711416045">a</xref></sup></td>
<td>2.44 ± 0.86</td>
<td>2.56 ± 1.02</td>
<td>2.62 ± 0.93</td>
<td>2.61 ± 0.96</td>
<td>2.62 ± 0.97</td>
<td>0.963</td></tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1.24 ± 0.37</td>
<td>1.36 ± 0.46</td>
<td>1.25 ± 0.37</td>
<td>1.24 ± 0.37</td>
<td>1.28 ± 0.41</td>
<td>0.263</td></tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.30 (1.00–1.61)</td>
<td>1.28 (0.94–1.90)</td>
<td>1.23 (0.92–1.82)</td>
<td>1.30 (0.91–1.90)</td>
<td>1.32 (0.97–1.90)</td>
<td>0.366</td></tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>6.1 ± 1.5</td>
<td>5.9 ± 1.6</td>
<td>6.2 ± 1.6</td>
<td>6.1 ± 1.6</td>
<td>6.3 ± 1.7</td>
<td>0.04</td></tr>
<tr>
<td>Insulin (mU/l)</td>
<td>10 (8–14)</td>
<td>9 (6–13)</td>
<td>10 (6–15)</td>
<td>10 (7–15)</td>
<td>10 (7–15)</td>
<td>0.023</td></tr>
<tr>
<td>HOMA IR</td>
<td>2.6 (1.8–4.1)</td>
<td>2.3 (1.5–3.4)</td>
<td>2.5 (1.6–4.0)</td>
<td>2.6 (1.6–4.0)</td>
<td>2.8 (1.7–4.5)</td>
<td>0.007</td></tr>
<tr>
<td>Homocysteine (umol/l)</td>
<td>13.3 ± 5.1</td>
<td>13.6 ± 4.5</td>
<td>13.1 ± 12.5</td>
<td>12.6 ± 5.2</td>
<td>12.8 ± 5.4</td>
<td>0.537</td></tr>
<tr>
<td>Creatinine (umol/l)</td>
<td>90.4 ± 29.2</td>
<td>97.7 ± 31.8</td>
<td>90.3 ± 21.8</td>
<td>91.8 ± 29.0</td>
<td>96.2 ± 55.4</td>
<td>0.006</td></tr>
<tr>
<td>eGFR (MDRD, ml/min/1.73 m<sup>2</sup>)</td>
<td>77.3 ± 18.4</td>
<td>70.3 ± 18.1</td>
<td>78.2 ± 17.3</td>
<td>77.0 ± 17.3</td>
<td>73.8 ± 18.1</td>
<td>&lt;0.001</td></tr>
<tr>
<td>hsCRP (mg/l)</td>
<td>1.9 (0.9–3.4)</td>
<td>2.0 (0.8–4.7)</td>
<td>1.8 (0.9–3.8)</td>
<td>1.7 (0.9–3.9)</td>
<td>1.9 (0.9–4.4)</td>
<td>0.298</td></tr>
<tr>
<td colspan="7">Medication use</td></tr>
<tr>
<td> Glucose-lowering medication</td>
<td>10 (11)</td>
<td>11 (13)</td>
<td>124 (15)</td>
<td>108 (13)</td>
<td>143 (18)</td>
<td>0.067</td></tr>
<tr>
<td> Blood pressure-lowering medication</td>
<td>35 (39)</td>
<td>36 (44)</td>
<td>400 (49)</td>
<td>383 (47)</td>
<td>405 (50)</td>
<td>0.62</td></tr>
<tr>
<td> Lipid-lowering medication</td>
<td>68 (76)</td>
<td>59 (72)</td>
<td>634 (77)</td>
<td>608 (75)</td>
<td>607 (75)</td>
<td>0.483</td></tr>
<tr>
<td colspan="7">Medical history</td></tr>
<tr>
<td> Diabetes mellitus</td>
<td>13 (14)</td>
<td>13 (16)</td>
<td>151 (18)</td>
<td>124 (15)</td>
<td>172 (21)</td>
<td>0.011</td></tr>
<tr>
<td> Coronary heart disease</td>
<td>64 (71)</td>
<td>49 (60)</td>
<td>557 (68)</td>
<td>531 (66)</td>
<td>495 (61)</td>
<td>0.007</td></tr>
<tr>
<td> Cerebrovascular disease</td>
<td>26 (29)</td>
<td>21 (26)</td>
<td>208 (25)</td>
<td>205 (25)</td>
<td>226 (28)</td>
<td>0.457</td></tr>
<tr>
<td> Peripheral arterial disease</td>
<td>15 (17)</td>
<td>12 (15)</td>
<td>130 (16)</td>
<td>126 (16)</td>
<td>150 (18)</td>
<td>0.242</td></tr>
<tr>
<td> Abdominal aortic aneurysm</td>
<td>7 (8)</td>
<td>3 (4)</td>
<td>61 (7)</td>
<td>44 (5)</td>
<td>65 (8)</td>
<td>0.106</td></tr>
<tr>
<td colspan="7">Measures of adiposity</td></tr>
<tr>
<td> Body mass index (kg/m<sup>2</sup>)</td>
<td>27.6 ± 3.7</td>
<td>27.0 ± 4.1</td>
<td>27.0 ± 4.1</td>
<td>27.2 ± 4.0</td>
<td>27.0 ± 4.1</td>
<td>0.802</td></tr>
<tr>
<td> Weight (kg)</td>
<td>83.6 ± 13.4</td>
<td>81.2 ± 14.7</td>
<td>82.8 ± 14.9</td>
<td>82.6 ± 14.8</td>
<td>81.5 ± 14.7</td>
<td>0.190</td></tr>
<tr>
<td> Waist circumference (cm)</td>
<td>97.0 ± 9.7</td>
<td>94.7 ± 12.4</td>
<td>95.1 ± 12.6</td>
<td>94.9 ± 12.3</td>
<td>94.6 ± 12.6</td>
<td>0.727</td></tr>
<tr>
<td> Visceral fat thickness (cm)</td>
<td>9.0 ± 2.4</td>
<td>8.7 ± 2.2</td>
<td>9.1 ± 2.5</td>
<td>9.0 ± 2.6</td>
<td>9.1 ± 2.6</td>
<td>0.880</td></tr>
<tr>
<td> Subcutaneous fat thickness (cm)</td>
<td>2.4 ± 1.3</td>
<td>2.3 ± 1.2</td>
<td>2.3 ± 1.2</td>
<td>2.2 ± 1.0</td>
<td>2.3 ± 1.4</td>
<td>0.225</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711416045"><p>Values are <italic>n</italic> (%), mean±standard deviation or median (interquartile range). <sup>a</sup>Calculated by use of the Friedewald formula. eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HOMA-IR, Homeostasis Model of Assessment − Insulin Resistance; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease; TSH, thyroid-stimulating hormone.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-1741826711416045"><title>Levels of TSH and the occurrence of new vascular events and all-cause mortality</title>
<p>During a median follow-up of 2.7 (interquartile range 1.4–3.9) years and a total follow-up of 6608 person-years, 82 patients (3.4%) died (of whom 49 from a cardiovascular cause) while 59 (2.4%) had a myocardial infarction and 29 patients (1.2%) had a stroke. The composite endpoint including myocardial infarction, stroke, abdominal aortic aneurysms, and other vascular events occurred in 107 patients (4.4%). With an increase of 1 mU/l TSH, the risk for the occurrence of myocardial infarction increased with 33% (HR 1.33; 95% CI 1.03–1.73) adjusted for age and gender. After additional adjustment for renal function and current smoking, the point estimate remained the same (HR 1.33; 95% CI 1.03–1.73) (<xref ref-type="table" rid="table2-1741826711416045">Table 2</xref>). In exploratory analyses we added beta-blocker use and the site of initial vascular disease to the models but these did not change the relations, neither did the addition of total cholesterol, HDL-cholesterol, the use of lipid-lowering agents, systolic blood pressure, and the use of blood pressure-lowering medication. Exclusion of patients with amiodarone or drondarone did not affect the results of the analyses. There was no relation between TSH and stroke, all vascular events, vascular death, or all-cause mortality.
<table-wrap id="table2-1741826711416045" position="float"><label>Table 2.</label><caption><p>Relation between plasma thyroid-stimulating hormone levels and occurrence of new vascular events and mortality</p></caption>
<graphic alternate-form-of="table2-1741826711416045" xlink:href="10.1177_1741826711416045-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th><italic>n </italic>= 2443</th>
<th>Model</th>
<th>No. of events</th>
<th>HR (95% CI)</th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="4">Myocardial infarction</td>
<td>I</td>
<td rowspan="4">59</td>
<td>1.33 (1.03–1.71)</td></tr>
<tr>
<td>II</td>
<td>1.33 (1.03–1.73)</td></tr>
<tr>
<td>III</td>
<td>1.33 (1.03–1.73)</td></tr>
<tr>
<td>IV</td>
<td>1.31 (1.01–1.69)</td></tr>
<tr>
<td rowspan="4">Stroke</td>
<td>I</td>
<td rowspan="4">29</td>
<td>1.01 (0.68–1.51)</td></tr>
<tr>
<td>II</td>
<td>0.99 (0.66–1.48)</td></tr>
<tr>
<td>III</td>
<td>0.96 (0.64–1.42)</td></tr>
<tr>
<td>IV</td>
<td>0.92 (0.62–1.38)</td></tr>
<tr>
<td rowspan="4">All vascular events</td>
<td>I</td>
<td rowspan="4">107</td>
<td>1.13 (0.94–1.39)</td></tr>
<tr>
<td>II</td>
<td>1.12 (0.91–1.37)</td></tr>
<tr>
<td>III</td>
<td>1.12 (0.91–1.36)</td></tr>
<tr>
<td>IV</td>
<td>1.10 (0.90–1.34)</td></tr>
<tr>
<td rowspan="4">All vascular death</td>
<td>I</td>
<td rowspan="4">49</td>
<td>0.98 (0.72–1.34)</td></tr>
<tr>
<td>II</td>
<td>0.96 (0.70–1.31)</td></tr>
<tr>
<td>III</td>
<td>0.96 (0.71–1.31)</td></tr>
<tr>
<td>IV</td>
<td>0.97 (0.71–1.32)</td></tr>
<tr>
<td rowspan="4">All-cause mortality</td>
<td>I</td>
<td rowspan="4">82</td>
<td>1.03 (0.81–1.30)</td></tr>
<tr>
<td>II</td>
<td>1.00 (0.79–1.26)</td></tr>
<tr>
<td>III</td>
<td>1.02 (0.81–1.29)</td></tr>
<tr>
<td>IV</td>
<td>1.02 (0.81–1.29)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1741826711416045"><p>Model I, crude model; Model II, adjusted for age and sex; Model III, adjusted for age, sex, Modification of Diet in Renal Disease (MDRD), and current smoking; Model IV, adjusted for age, sex, MDRD, current smoking, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering agents, systolic blood pressure, and blood pressure-lowering medication. Hazard ratio (HR) of 1.31 implies that, per increase of 1 mU/l in plasma thyroid-stimulating hormone level within the normal range, the risk for that endpoint increases by 31%.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec10-1741826711416045"><title>Influence of adiposity on the relation between TSH and new vascular events and all-cause mortality</title>
<p>Stratified analyses were performed for measures of adiposity (BMI, waist circumference, and visceral adipose tissue) to evaluate the influence of adiposity on the relation between TSH and vascular events and all-cause mortality (<xref ref-type="table" rid="table3-1741826711416045">Table 3</xref>.). In patients with a BMI below the median (≤26.6 kg/m<sup>2</sup>) the risk for myocardial infarction increased with 55% for each 1 mU/l increase in TSH (HR 1.55; 95% CI 1.08–2.21) compared to an 18% increased risk (HR 1.18; 95% CI 0.81⊟1.71) in patients with a BMI ≥26.7 kg/m<sup>2</sup>. Results after stratification for BMI using standard cut-off values of BMI are shown in Supplementary <xref ref-type="table" rid="table1-1741826711416045">Table 1</xref>. For waist circumference below the median (≤95 cm) the risk for myocardial infarction increased with 49% for each 1 mU/l increase in TSH (HR 1.49; 95% CI 1.04⊟2.11) compared to 20% (HR 1.20; 95% CI 0.82⊟1.76) in patients with a waist circumference ≥96 cm. Patients with visceral adipose tissue thickness below the median (≤8.8 cm) had an increased risk for myocardial infarction of 69% for each increase in one mU/l of TSH (HR 1.69; 95% CI 1.21–2.35) compared to no effect of TSH on myocardial infarction risk in patients with a visceral adipose tissue thickness ≥8.9 cm (HR 1.00; 95% CI 0.66⊟1.49). There was no influence of (absence of) adiposity on the relation between plasma TSH levels and the risk of stroke, all vascular events, vascular death, or all-cause mortality.
<table-wrap id="table3-1741826711416045" position="float"><label>Table 3.</label><caption><p>Relation between plasma TSH levels within the normal range and the occurrence of new vascular events stratified for adiposity</p></caption>
<graphic alternate-form-of="table3-1741826711416045" xlink:href="10.1177_1741826711416045-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="5"/><th rowspan="5">Model</th>
<th colspan="4">Body mass index<hr/></th>
<th colspan="4">Waist circumference<sup>a</sup><hr/></th>
<th colspan="4">Visceral adipose tissue<sup>a</sup><hr/></th></tr>
<tr><th colspan="2">Low (below median)<hr/></th>
<th colspan="2">High (above median)<hr/></th>
<th colspan="2">Low (below median)<hr/></th>
<th colspan="2">High (above median)<hr/></th>
<th colspan="2">Low (below median)<hr/></th>
<th colspan="2">High (above median)<hr/></th></tr>
<tr><th colspan="2">23.9 kg/m<sup>2</sup> (15.4–26.6)<hr/></th>
<th colspan="2">30.2 kg/m<sup>2</sup> (26.7–49.3)<hr/></th>
<th colspan="2">85 cm (59–94)<hr/></th>
<th colspan="2">105 cm (95–149)<hr/></th>
<th colspan="2">7.1 cm (2.7–8.8)<hr/></th>
<th colspan="2">11.0 cm (8.9–20.2)<hr/></th></tr>
<tr><th colspan="2"><italic>n </italic>= 1220<hr/></th>
<th colspan="2"><italic>n </italic>= 1223<hr/></th>
<th colspan="2"><italic>n </italic>= 1188<hr/></th>
<th colspan="2"><italic>n </italic>= 1255<hr/></th>
<th colspan="2"><italic>n </italic>= 1213<hr/></th>
<th colspan="2"><italic>n </italic>= 1230<hr/></th></tr>
<tr><th>No. of events</th>
<th>HR (95% CI)</th>
<th>No. of events</th>
<th>HR (95% CI)</th>
<th>No. of events</th>
<th>HR (95% CI)</th>
<th>No. of events</th>
<th>HR (95% CI)</th>
<th>No. of events</th>
<th>HR (95% CI)</th>
<th>No. of events</th>
<th>HR (95% CI)</th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="4">Myocardial infarction</td>
<td>I</td>
<td rowspan="4">28</td>
<td>1.58 (1.10–2.27)</td>
<td rowspan="4">31</td>
<td>1.14 (0.79–1.64)</td>
<td rowspan="4">28</td>
<td>1.50 (1.05–2.14)</td>
<td rowspan="4">31</td>
<td>1.18 (0.81–1.71)</td>
<td rowspan="4">30</td>
<td>1.67 (1.18–2.35)</td>
<td rowspan="4">29</td>
<td>1.03 (0.70–1.52)</td></tr>
<tr>
<td>II</td>
<td>1.52 (1.06–2.18)</td>
<td>1.20 (0.83–1.74)</td>
<td>1.45 (1.01–2.07)</td>
<td>1.21 (0.83–1.77)</td>
<td>1.67 (1.18–2.35)</td>
<td>1.04 (0.70–1.54)</td></tr>
<tr>
<td>III</td>
<td>1.55 (1.08–2.21)</td>
<td>1.18 (0.81–1.71)</td>
<td>1.49 (1.04–2.11)</td>
<td>1.20 (0.82–1.76)</td>
<td>1.69 (1.21–2.35)</td>
<td>1.00 (0.66–1.49)</td></tr>
<tr>
<td>IV</td>
<td>1.51 (1.05–2.15)</td>
<td>1.18 (0.81–1.71)</td>
<td>1.42 (0.99–2.04)</td>
<td>1.20 (0.82–1.75)</td>
<td>1.65 (1.17–2.32)</td>
<td>0.99 (0.66–1.49)</td></tr>
<tr>
<td rowspan="4">Stroke</td>
<td>I</td>
<td rowspan="4">16</td>
<td>0.91 (0.52–1.62)</td>
<td rowspan="4">13</td>
<td>1.13 (0.64–1.98)</td>
<td rowspan="4">13</td>
<td>0.69 (0.35–1.38)</td>
<td rowspan="4">16</td>
<td>1.31 (0.80–2.17)</td>
<td rowspan="4">12</td>
<td>0.75 (0.37–1.52)</td>
<td rowspan="4">17</td>
<td>1.20 (0.74–1.95)</td></tr>
<tr>
<td>II</td>
<td>0.91 (0.52–1.60)</td>
<td>1.09 (0.62–1.93)</td>
<td>0.71 (0.35–1.40)</td>
<td>1.26 (0.77–2.06)</td>
<td>0.75 (0.37–1.51)</td>
<td>1.16 (0.71–1.89)</td></tr>
<tr>
<td>III</td>
<td>0.86 (0.49–1.53)</td>
<td>1.07 (0.62–1.86)</td>
<td>0.69 (0.35–1.35)</td>
<td>1.22 (0.74–1.99)</td>
<td>0.75 (0.37–1.49)</td>
<td>1.09 (0.66–1.78)</td></tr>
<tr>
<td>IV</td>
<td>0.86 (0.49–1.53)</td>
<td>1.09 (0.62–1.92)</td>
<td>0.63 (0.32–1.24)</td>
<td>1.22 (0.75–1.98)</td>
<td>0.74 (0.37–1.48)</td>
<td>1.07 (0.64–1.79)</td></tr>
<tr>
<td rowspan="4">All vascular events</td>
<td>I</td>
<td rowspan="4">49</td>
<td>1.25 (0.93–1.68)</td>
<td rowspan="4">58</td>
<td>1.05 (0.79–1.38)</td>
<td rowspan="4">45</td>
<td>1.21 (0.90–1.63)</td>
<td rowspan="4">62</td>
<td>1.09 (0.83–1.43)</td>
<td rowspan="4">47</td>
<td>1.31 (0.98–1.76)</td>
<td rowspan="4">60</td>
<td>1.01 (0.76–1.33)</td></tr>
<tr>
<td>II</td>
<td>1.22 (0.91–1.62)</td>
<td>1.05 (0.79–1.39)</td>
<td>1.16 (0.86–1.57)</td>
<td>1.08 (0.82–1.42)</td>
<td>1.30 (0.97–1.73)</td>
<td>0.99 (0.75–1.30)</td></tr>
<tr>
<td>III</td>
<td>1.24 (0.93–1.65)</td>
<td>1.03 (0.78–1.37)</td>
<td>1.19 (0.89–1.60)</td>
<td>1.07 (0.81–1.41)</td>
<td>1.32 (1.00–1.76)</td>
<td>0.96 (0.73–1.28)</td></tr>
<tr>
<td>IV</td>
<td>1.23 (0.92–1.64)</td>
<td>1.02 (0.77–1.35)</td>
<td>1.15 (0.86–1.55)</td>
<td>1.06 (0.81–1.40)</td>
<td>1.30 (0.97–1.73)</td>
<td>0.96 (0.72–1.27)</td></tr>
<tr>
<td rowspan="4">All vascular death</td>
<td>I</td>
<td rowspan="4">21</td>
<td>1.16 (0.74–1.84)</td>
<td rowspan="4">28</td>
<td>0.86 (0.56–1.33)</td>
<td rowspan="4">19</td>
<td>1.06 (0.66–1.72)</td>
<td rowspan="4">30</td>
<td>0.94 (0.62–1.42)</td>
<td rowspan="4">17</td>
<td>0.95 (0.55–1.63)</td>
<td rowspan="4">32</td>
<td>1.00 (0.69–1.46)</td></tr>
<tr>
<td>II</td>
<td>1.13 (0.72–1.78)</td>
<td>0.82 (0.53–1.27)</td>
<td>1.02 (0.63–1.64)</td>
<td>0.90 (0.60–1.36)</td>
<td>0.93 (0.54–1.60)</td>
<td>0.95 (0.65–1.38)</td></tr>
<tr>
<td>III</td>
<td>1.20 (0.77–1.87)</td>
<td>0.81 (0.52–1.26)</td>
<td>1.05 (0.66–1.68)</td>
<td>0.89 (0.59–1.35)</td>
<td>0.97 (0.57–1.65)</td>
<td>0.94 (0.66–1.38)</td></tr>
<tr>
<td>IV</td>
<td>1.20 (0.77–1.86)</td>
<td>0.83 (0.54–1.28)</td>
<td>1.04 (0.65–1.66)</td>
<td>0.88 (0.58–1.33)</td>
<td>0.96 (0.57–1.63)</td>
<td>0.94 (0.64–1.39)</td></tr>
<tr>
<td rowspan="4">All-cause mortality</td>
<td>I</td>
<td rowspan="4">34</td>
<td>1.17 (0.82–1.68)</td>
<td rowspan="4">48</td>
<td>0.94 (0.69–1.28)</td>
<td rowspan="4">32</td>
<td>1.16 (0.81–1.66)</td>
<td rowspan="4">50</td>
<td>0.95 (0.69–1.31)</td>
<td rowspan="4">31</td>
<td>1.01 (0.68–1.49)</td>
<td rowspan="4">51</td>
<td>1.04 (0.78–1.40)</td></tr>
<tr>
<td>II</td>
<td>1.13 (0.79–1.62)</td>
<td>0.89 (0.65–1.23)</td>
<td>1.10 (0.77–1.56)</td>
<td>0.91 (0.66–1.25)</td>
<td>0.98 (0.66–1.44)</td>
<td>0.99 (0.74–1.33)</td></tr>
<tr>
<td>III</td>
<td>1.21 (0.85–1.70)</td>
<td>0.89 (0.65–1.22)</td>
<td>1.15 (0.81–1.64)</td>
<td>0.91 (0.66–1.25)</td>
<td>1.04 (0.72–1.51)</td>
<td>1.00 (0.74–1.34)</td></tr>
<tr>
<td>IV</td>
<td>1.22 (0.86–1.73)</td>
<td>0.90 (0.65–1.23)</td>
<td>1.19 (0.83–1.69)</td>
<td>0.91 (0.66–1.25)</td>
<td>1.07 (0.73–1.56)</td>
<td>1.00 (0.74–1.35)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711416045"><p>Values are hazard ratios (95% confidence intervals). Values for low and high groups are mean (range). Model I, crude model; Model II, adjusted for age and sex; Model III, adjusted for age, sex, Modification of Diet in Renal Disease (MDRD), and current smoking; Model IV, adjusted for age, sex, MDRD, current smoking, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering agents, systolic blood pressure, and blood pressure-lowering medication. Hazard ratio (HR) of 1.51 implies that per increase of 1 mU/l in plasma thyroid-stimulating hormone level within the normal range, the risk for that endpoint increases by 51%.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
</sec>
<sec id="sec11-1741826711416045" sec-type="discussion"><title>Discussion</title>
<p>In patients with manifest vascular disease the prevalence of (subclinical) hypothyroidism was 5.7%, while 3.6% had (subclinical) hyperthyroidism. Higher levels of TSH within the normal range are associated with an increased risk of myocardial infarction. This relation is most prominent in patients with normal BMI, normal waist circumference. and low visceral adipose tissue thickness.</p>
<p>In a recent study in subjects without cardiovascular disease or diabetes, the prevalence of TSH below 0.5 mU/l was 2.2% while 7.3% of the population had plasma TSH level above 3.5 mU/l.<sup><xref ref-type="bibr" rid="bibr15-1741826711416045">15</xref></sup> When these cut-off values are applied to the present study in patients with clinical manifest vascular diseases, the prevalence of plasma TSH levels below and above the normal range would be 3.8% and 10.8% respectively, revealing a higher prevalence of thyroid dysfunction in these patients. Both vascular diseases and diabetes are associated with a higher plasma interleukin 6 level (IL-6)<sup><xref ref-type="bibr" rid="bibr24-1741826711416045">24</xref>,<xref ref-type="bibr" rid="bibr25-1741826711416045">25</xref></sup> which is related to the presence of non-thyroidal illness syndrome otherwise known as sick euthyroid syndrome.<sup><xref ref-type="bibr" rid="bibr26-1741826711416045">26</xref></sup> Therefore it is conceivable that our study population has a higher prevalence of plasma TSH levels outside the normal range due to the presence of non-thyroidal illness syndrome. Although non-thyroidal illness syndrome is commonly associated with normal plasma TSH levels, increases in plasma TSH level do occur, especially in the recovery phase.<sup><xref ref-type="bibr" rid="bibr27-1741826711416045">27</xref>,<xref ref-type="bibr" rid="bibr28-1741826711416045">28</xref></sup> Since patients were not included in the present cohort study within the first weeks after a vascular event, it is unlikely that plasma TSH levels were directly affected by the vascular event itself.<sup><xref ref-type="bibr" rid="bibr29-1741826711416045">29</xref>,<xref ref-type="bibr" rid="bibr30-1741826711416045">30</xref></sup> Another plausible explanation for the higher prevalence could be that overt and subclinical thyroid function disorders are associated with cardiovascular risk factors, which lead to a higher risk for cardiovascular diseases. The prevalence of thyroid disorders would therefore be higher in patients with vascular diseases compared to subjects without. The clinical consequence of this finding could be that clinicians involved in the treatment of patients with vascular diseases should be alert to the possibility of the presence of (subclinical) hypo- or hyperthyroidism.</p>
<p>In a recent population wide study in subjects without cardiovascular disease, plasma TSH levels within the normal range were associated with an increased risk for fatal coronary artery disease, although this was only apparent in women.<sup><xref ref-type="bibr" rid="bibr15-1741826711416045">15</xref></sup> The present study expands these data to patients with clinical manifestations of vascular diseases, showing an increased risk for myocardial infarction with higher plasma levels of TSH in the normal range in both men and women. For example, a patient with a clinical manifestation of a vascular disease with a plasma TSH level of 3.0 mU/l has a 66% higher risk of myocardial infarction than a patient with the same medical history and a plasma TSH level of 1.0 mU/l. Our data concur with the results from an earlier population study in elderly patients which showed no relation between plasma TSH levels within the normal range and death from cardiovascular disease. We too showed no relation between plasma TSH levels in the normal range and vascular death or total mortality, but did show a relation with new myocardial infarction.<sup><xref ref-type="bibr" rid="bibr31-1741826711416045">31</xref></sup> The number of patients with an event in our study with a plasma TSH level below or above the normal range was too small to study the relation between TSH and new cardiovascular events in these two groups.</p>
<p>As plasma TSH levels are a reflection of thyroid function, the relation between TSH and new cardiovascular events could be explained by the various metabolic and vascular effects of thyroid hormones. For example, hypothyroidism is associated with a higher plasma level of LDL cholesterol which is caused by a reduction in the expression of the LDL receptor.<sup><xref ref-type="bibr" rid="bibr6-1741826711416045">6</xref>,<xref ref-type="bibr" rid="bibr32-1741826711416045">32</xref></sup> Although the precise mechanism is not completely understood, low plasma thyroid hormone levels are also associated with increased plasma C-reactive protein levels in patients with hypothyroidism.<sup><xref ref-type="bibr" rid="bibr5-1741826711416045">5</xref></sup> However, there was no difference in the plasma levels of both LDL-cholesterol and C-reactive protein between the tertiles of plasma TSH (<xref ref-type="table" rid="table1-1741826711416045">Table 1</xref>.).</p>
<p>After correction for other factors, plasma TSH levels in the highest quartile are associated with impairment of endothelial function as measured by flow-mediated dilatation.<sup><xref ref-type="bibr" rid="bibr33-1741826711416045">33</xref></sup> It is not clear whether the relation between plasma TSH levels and endothelial function reflects a direct effect of thyroid hormone or plasma TSH on endothelial function or whether both are reflections of inflammation.<sup><xref ref-type="bibr" rid="bibr24-1741826711416045">24</xref>,<xref ref-type="bibr" rid="bibr34-1741826711416045">34</xref></sup> Although controversial, TSH itself may also have direct detrimental vascular effects as witnessed by a reduction in flow-mediated dilatation after injection of recombinant TSH.<sup><xref ref-type="bibr" rid="bibr35-1741826711416045">35</xref>,<xref ref-type="bibr" rid="bibr36-1741826711416045">36</xref></sup></p>
<p>There is a strong relation between higher TSH levels within the normal range and increased bodyweight and BMI, pointing to the possibility that changes in thyroid function might influence adiposity or vice versa.<sup><xref ref-type="bibr" rid="bibr16-1741826711416045">16</xref>,<xref ref-type="bibr" rid="bibr17-1741826711416045">17</xref></sup> We recently showed in a similar study population of patients with manifest vascular disease that TSH levels in the normal range are associated with visceral adipose tissue thickness.<sup><xref ref-type="bibr" rid="bibr37-1741826711416045">37</xref></sup> In addition, changes in plasma TSH levels are associated with changes in bodyweight.<sup><xref ref-type="bibr" rid="bibr16-1741826711416045">16</xref></sup> Rapid decreases in bodyweight as with bariatric surgery are associated with a decrease in the plasma TSH level suggesting a direct influence of bodyweight on plasma TSH.<sup><xref ref-type="bibr" rid="bibr38-1741826711416045">38</xref></sup> The relation between bodyweight and plasma TSH could be explained by the interplay between leptin and TSH. The adipokine leptin is released from adipose tissue and increases the hypothalamic release of thyroid-releasing hormone which subsequently influences plasma TSH levels. By this mechanism one could argue that TSH plasma levels are also a reflection of adipose tissue leptin production.<sup><xref ref-type="bibr" rid="bibr18-1741826711416045">18</xref></sup> The relation between TSH plasma levels within the normal range and the increased risk for myocardial infarction could partly be explained by the relation with adiposity and subsequent metabolic changes, including insulin resistance and inflammation. The vascular risk of obesity is well established.<sup><xref ref-type="bibr" rid="bibr39-1741826711416045">39</xref></sup> In the present study we showed that the relation between TSH and cardiovascular risk in patients with clinical manifest vascular diseases was modified by adiposity, as measured by BMI, waist circumference, and especially visceral adipose tissue thickness. Patients with measures of adiposity below the median had the strongest relation between plasma TSH levels and myocardial infarction. Although not statistically significant, the relation between TSH and the risk of stroke was strongest in patients above the median of measures of adiposity. This differential modification of the relation between plasma TSH levels and new vascular events by adiposity after correction of age, sex, renal function, and current smoking warrants further investigation. Why TSH is associated with the highest risk for myocardial infarction in patients with normal bodyweight, in contrast to patient with overweight is unknown. The relation between plasma TSH levels and myocardial infarction could be explained by the effects of both plasma TSH and thyroid hormones on lipids, inflammation, and endothelial dysfunction. However, adiposity itself is also strongly correlated with, amongst others, lipids, inflammation, and endothelial dysfunction.<sup><xref ref-type="bibr" rid="bibr40-1741826711416045">40</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr42-1741826711416045">42</xref></sup> One could therefore speculate that the modification of the relation between plasma TSH levels and myocardial infarction by adiposity is due to relatively small added risk in obese patients. These obese patients already have a higher risk for new cardiovascular events than lean patients. This same added absolute risk conferred by plasma TSH levels has relatively greater implications in patients with a lower risk for cardiovascular disease, such as lean patients.</p>
<p>One of the strengths of this study is the large study group of a relevant and well-characterized group of patients with clinical manifestations of vascular diseases. We were able to exclude patients from analyses who received thyroid hormone supplementation, strumazol or propylthiouracil. An obvious weakness in this study is the absence of information on plasma thyroid hormone levels. We can therefore not exclude the possibility that this study population might still contain patients with rarer causes of thyroid dysfunction, but given the low prevalence it is unlikely that this will affect the study results. Furthermore, in our prevalence data we cannot differentiate between those patients with subclinical and overt hypo- or hyperthyroidism.</p>
<p>In conclusion, the prevalence of plasma TSH levels above and below the normal range in patients with manifest vascular disease is higher than in the general population. Within the normal range, a higher plasma TSH level is associated with an increased risk of myocardial infarction, in patients with manifest vascular disease. This relation is most prominent in patients without visceral obesity.</p>
</sec>
</body>
<back>
<sec id="sec12-1741826711416045"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec13-1741826711416045"><title>Conflict of interest</title>
<p>The authors report no conflicts of interest.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711416045"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Palmieri</surname><given-names>EA</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name><name><surname>Biondi</surname><given-names>B</given-names></name></person-group>. <article-title>Effects of thyroid hormone on the cardiovascular system</article-title>. <source>Recent Prog Horm Res</source> <year>2004</year>; <volume>59</volume>(<issue>1</issue>): <fpage>31</fpage>–<lpage>50</lpage>.</citation></ref>
<ref id="bibr2-1741826711416045"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luboshitzky</surname><given-names>R</given-names></name><name><surname>Aviv</surname><given-names>A</given-names></name><name><surname>Herer</surname><given-names>P</given-names></name><name><surname>Lavie</surname><given-names>L</given-names></name></person-group>. <article-title>Risk factors for cardiovascular disease in women with subclinical hypothyroidism</article-title>. <source>Thyroid</source> <year>2002</year>; <volume>12</volume>(<issue>5</issue>): <fpage>421</fpage>–<lpage>425</lpage>.</citation></ref>
<ref id="bibr3-1741826711416045"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crowley</surname><given-names>WF</given-names><suffix>Jr</suffix></name><name><surname>Ridgway</surname><given-names>EC</given-names></name><name><surname>Bough</surname><given-names>EW</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><name><surname>Daniels</surname><given-names>GH</given-names></name><name><surname>Kourides</surname><given-names>IA</given-names></name><etal/></person-group>. <article-title>Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement</article-title>. <source>N Engl J Med</source> <year>1977</year>; <volume>296</volume>(<issue>1</issue>): <fpage>1</fpage>–<lpage>6</lpage>.</citation></ref>
<ref id="bibr4-1741826711416045"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gumieniak</surname><given-names>O</given-names></name><name><surname>Perlstein</surname><given-names>TS</given-names></name><name><surname>Hopkins</surname><given-names>PN</given-names></name><name><surname>Brown</surname><given-names>NJ</given-names></name><name><surname>Murphey</surname><given-names>LJ</given-names></name><name><surname>Jeunemaitre</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Thyroid function and blood pressure homeostasis in euthyroid subjects</article-title>. <source>J Clin Endocrinol Metab</source> <year>2004</year>; <volume>89</volume>(<issue>7</issue>): <fpage>3455</fpage>–<lpage>3461</lpage>.</citation></ref>
<ref id="bibr5-1741826711416045"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jublanc</surname><given-names>C</given-names></name><name><surname>Bruckert</surname><given-names>E</given-names></name><name><surname>Giral</surname><given-names>P</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Leenhardt</surname><given-names>L</given-names></name><name><surname>Carreau</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP</article-title>. <source>Atherosclerosis</source> <year>2004</year>; <volume>172</volume>(<issue>1</issue>): <fpage>7</fpage>–<lpage>11</lpage>.</citation></ref>
<ref id="bibr6-1741826711416045"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>T</given-names></name><name><surname>Dinneen</surname><given-names>SF</given-names></name><name><surname>O'Brien</surname><given-names>PC</given-names></name><name><surname>Palumbo</surname><given-names>PJ</given-names></name></person-group>. <article-title>Hyperlipidemia in patients with primary and secondary hypothyroidism</article-title>. <source>Mayo Clin Proc</source> <year>1993</year>; <volume>68</volume>(<issue>9</issue>): <fpage>860</fpage>–<lpage>866</lpage>.</citation></ref>
<ref id="bibr7-1741826711416045"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papaioannou</surname><given-names>GI</given-names></name><name><surname>Lagasse</surname><given-names>M</given-names></name><name><surname>Mather</surname><given-names>JF</given-names></name><name><surname>Thompson</surname><given-names>PD</given-names></name></person-group>. <article-title>Treating hypothyroidism improves endothelial function</article-title>. <source>Metabolism</source> <year>2004</year>; <volume>53</volume>(<issue>3</issue>): <fpage>278</fpage>–<lpage>279</lpage>.</citation></ref>
<ref id="bibr8-1741826711416045"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiche</surname><given-names>F</given-names></name><name><surname>Jublanc</surname><given-names>C</given-names></name><name><surname>Coudert</surname><given-names>M</given-names></name><name><surname>Carreau</surname><given-names>V</given-names></name><name><surname>Kahn</surname><given-names>JF</given-names></name><name><surname>Bruckert</surname><given-names>E</given-names></name></person-group>. <article-title>Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patients</article-title>. <source>Atherosclerosis</source> <year>2009</year>; <volume>203</volume>(<issue>1</issue>): <fpage>269</fpage>–<lpage>276</lpage>.</citation></ref>
<ref id="bibr9-1741826711416045"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monzani</surname><given-names>F</given-names></name><name><surname>Caraccio</surname><given-names>N</given-names></name><name><surname>Kozakowa</surname><given-names>M</given-names></name><name><surname>Dardano</surname><given-names>A</given-names></name><name><surname>Vittone</surname><given-names>F</given-names></name><name><surname>Virdis</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study</article-title>. <source>J Clin Endocrinol Metab</source> <year>2004</year>; <volume>89</volume>(<issue>5</issue>): <fpage>2099</fpage>–<lpage>2106</lpage>.</citation></ref>
<ref id="bibr10-1741826711416045"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gussekloo</surname><given-names>J</given-names></name><name><surname>van</surname><given-names>EE</given-names></name><name><surname>de Craen</surname><given-names>AJ</given-names></name><name><surname>Meinders</surname><given-names>AE</given-names></name><name><surname>Frolich</surname><given-names>M</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name></person-group>. <article-title>Thyroid status, disability and cognitive function, and survival in old age</article-title>. <source>JAMA</source> <year>2004</year>; <volume>292</volume>(<issue>21</issue>): <fpage>2591</fpage>–<lpage>2599</lpage>.</citation></ref>
<ref id="bibr11-1741826711416045"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ochs</surname><given-names>N</given-names></name><name><surname>Auer</surname><given-names>R</given-names></name><name><surname>Bauer</surname><given-names>DC</given-names></name><name><surname>Nanchen</surname><given-names>D</given-names></name><name><surname>Gussekloo</surname><given-names>J</given-names></name><name><surname>Cornuz</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality</article-title>. <source>Ann Intern Med</source> <year>2008</year>; <volume>148</volume>(<issue>11</issue>): <fpage>832</fpage>–<lpage>845</lpage>.</citation></ref>
<ref id="bibr12-1741826711416045"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodondi</surname><given-names>N</given-names></name><name><surname>den Elzen</surname><given-names>WP</given-names></name><name><surname>Bauer</surname><given-names>DC</given-names></name><name><surname>Cappola</surname><given-names>AR</given-names></name><name><surname>Razvi</surname><given-names>S</given-names></name><name><surname>Walsh</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>Subclinical hypothyroidism and the risk of coronary heart disease and mortality</article-title>. <source>JAMA</source> <year>2010</year>; <volume>304</volume>(<issue>12</issue>): <fpage>1365</fpage>–<lpage>1374</lpage>.</citation></ref>
<ref id="bibr13-1741826711416045"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cikim</surname><given-names>AS</given-names></name><name><surname>Oflaz</surname><given-names>H</given-names></name><name><surname>Ozbey</surname><given-names>N</given-names></name><name><surname>Cikim</surname><given-names>K</given-names></name><name><surname>Umman</surname><given-names>S</given-names></name><name><surname>Meric</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism</article-title>. <source>Thyroid</source> <year>2004</year>; <volume>14</volume>(<issue>8</issue>): <fpage>605</fpage>–<lpage>609</lpage>.</citation></ref>
<ref id="bibr14-1741826711416045"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kvetny</surname><given-names>J</given-names></name><name><surname>Heldgaard</surname><given-names>PE</given-names></name><name><surname>Bladbjerg</surname><given-names>EM</given-names></name><name><surname>Gram</surname><given-names>J</given-names></name></person-group>. <article-title>Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years</article-title>. <source>Clin Endocrinol (Oxf)</source> <year>2004</year>; <volume>61</volume>(<issue>2</issue>): <fpage>232</fpage>–<lpage>238</lpage>.</citation></ref>
<ref id="bibr15-1741826711416045"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asvold</surname><given-names>BO</given-names></name><name><surname>Bjoro</surname><given-names>T</given-names></name><name><surname>Nilsen</surname><given-names>TI</given-names></name><name><surname>Gunnell</surname><given-names>D</given-names></name><name><surname>Vatten</surname><given-names>LJ</given-names></name></person-group>. <article-title>Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study</article-title>. <source>Arch Intern Med</source> <year>2008</year>; <volume>168</volume>(<issue>8</issue>): <fpage>855</fpage>–<lpage>860</lpage>.</citation></ref>
<ref id="bibr16-1741826711416045"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>CS</given-names></name><name><surname>Pencina</surname><given-names>MJ</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names></name><name><surname>Murabito</surname><given-names>JM</given-names></name><name><surname>Seely</surname><given-names>EW</given-names></name><name><surname>Pearce</surname><given-names>EN</given-names></name><etal/></person-group>. <article-title>Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample</article-title>. <source>Arch Intern Med</source> <year>2008</year>; <volume>168</volume>(<issue>6</issue>): <fpage>587</fpage>–<lpage>592</lpage>.</citation></ref>
<ref id="bibr17-1741826711416045"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>N</given-names></name><name><surname>Laurberg</surname><given-names>P</given-names></name><name><surname>Rasmussen</surname><given-names>LB</given-names></name><name><surname>Bulow</surname><given-names>I</given-names></name><name><surname>Perrild</surname><given-names>H</given-names></name><name><surname>Ovesen</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population</article-title>. <source>J Clin Endocrinol Metab</source> <year>2005</year>; <volume>90</volume>(<issue>7</issue>): <fpage>4019</fpage>–<lpage>4024</lpage>.</citation></ref>
<ref id="bibr18-1741826711416045"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Small</surname><given-names>CJ</given-names></name><name><surname>Stanley</surname><given-names>SA</given-names></name><name><surname>Morgan</surname><given-names>DG</given-names></name><name><surname>Seal</surname><given-names>LJ</given-names></name><name><surname>Kong</surname><given-names>WM</given-names></name><etal/></person-group>. <article-title>The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin</article-title>. <source>J Clin Invest</source> <year>2000</year>; <volume>105</volume>(<issue>7</issue>): <fpage>1005</fpage>–<lpage>1011</lpage>.</citation></ref>
<ref id="bibr19-1741826711416045"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hubert</surname><given-names>HB</given-names></name><name><surname>Feinleib</surname><given-names>M</given-names></name><name><surname>McNamara</surname><given-names>PM</given-names></name><name><surname>Castelli</surname><given-names>WP</given-names></name></person-group>. <article-title>Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study</article-title>. <source>Circulation</source> <year>1983</year>; <volume>67</volume>(<issue>5</issue>): <fpage>968</fpage>–<lpage>977</lpage>.</citation></ref>
<ref id="bibr20-1741826711416045"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simons</surname><given-names>PC</given-names></name><name><surname>Algra</surname><given-names>A</given-names></name><name><surname>van de Laak</surname><given-names>MF</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>van der</surname><given-names>GY</given-names></name></person-group>. <article-title>Second manifestations of ARTerial disease (SMART) study: rationale and design</article-title>. <source>Eur J Epidemiol</source> <year>1999</year>; <volume>15</volume>(<issue>9</issue>): <fpage>773</fpage>–<lpage>781</lpage>.</citation></ref>
<ref id="bibr21-1741826711416045"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Wink</surname><given-names>O</given-names></name><name><surname>Zelissen</surname><given-names>PM</given-names></name><name><surname>Meijer</surname><given-names>R</given-names></name><name><surname>van Gils</surname><given-names>AP</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name></person-group>. <article-title>Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue</article-title>. <source>Int J Obes Relat Metab Disord</source> <year>2001</year>; <volume>25</volume>(<issue>9</issue>): <fpage>1346</fpage>–<lpage>1351</lpage>.</citation></ref>
<ref id="bibr22-1741826711416045"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asvold</surname><given-names>BO</given-names></name><name><surname>Bjoro</surname><given-names>T</given-names></name><name><surname>Nilsen</surname><given-names>TI</given-names></name><name><surname>Vatten</surname><given-names>LJ</given-names></name></person-group>. <article-title>Tobacco smoking and thyroid function: a population-based study</article-title>. <source>Arch Intern Med</source> <year>2007</year>; <volume>167</volume>(<issue>13</issue>): <fpage>1428</fpage>–<lpage>1432</lpage>.</citation></ref>
<ref id="bibr23-1741826711416045"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G</given-names></name><name><surname>Montagnana</surname><given-names>M</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Salvagno</surname><given-names>GL</given-names></name><name><surname>Guidi</surname><given-names>GC</given-names></name></person-group>. <article-title>Relationship between thyroid status and renal function in a general population of unselected outpatients</article-title>. <source>Clin Biochem</source> <year>2008</year>; <volume>41</volume>(<issue>7⊟8</issue>): <fpage>625</fpage>–<lpage>627</lpage>.</citation></ref>
<ref id="bibr24-1741826711416045"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yudkin</surname><given-names>JS</given-names></name><name><surname>Kumari</surname><given-names>M</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Mohamed-Ali</surname><given-names>V</given-names></name></person-group>. <article-title>Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?</article-title>. <source>Atherosclerosis</source> <year>2000</year>; <volume>148</volume>(<issue>2</issue>): <fpage>209</fpage>–<lpage>214</lpage>.</citation></ref>
<ref id="bibr25-1741826711416045"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname><given-names>AD</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group>. <article-title>C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus</article-title>. <source>JAMA</source> <year>2001</year>; <volume>286</volume>(<issue>3</issue>): <fpage>327</fpage>–<lpage>334</lpage>.</citation></ref>
<ref id="bibr26-1741826711416045"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>PH</given-names></name><name><surname>Black</surname><given-names>EG</given-names></name><name><surname>Sheppard</surname><given-names>MC</given-names></name><name><surname>Franklyn</surname><given-names>JA</given-names></name></person-group>. <article-title>Relation between serum interleukin⊟6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness</article-title>. <source>Clin Endocrinol (Oxf)</source> <year>1996</year>; <volume>44</volume>(<issue>2</issue>): <fpage>199</fpage>–<lpage>205</lpage>.</citation></ref>
<ref id="bibr27-1741826711416045"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Groot</surname><given-names>LJ</given-names></name></person-group>. <article-title>Dangerous dogmas in medicine: the nonthyroidal illness syndrome</article-title>. <source>J Clin Endocrinol Metab</source> <year>1999</year>; <volume>84</volume>(<issue>1</issue>): <fpage>151</fpage>–<lpage>164</lpage>.</citation></ref>
<ref id="bibr28-1741826711416045"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>CA</given-names></name><name><surname>Lopresti</surname><given-names>JS</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Guttler</surname><given-names>RB</given-names></name><name><surname>Eigen</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Applications of a new chemiluminometric thyrotropin assay to subnormal measurement</article-title>. <source>J Clin Endocrinol Metab</source> <year>1990</year>; <volume>70</volume>(<issue>2</issue>): <fpage>453</fpage>–<lpage>460</lpage>.</citation></ref>
<ref id="bibr29-1741826711416045"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name><name><surname>Kotajima</surname><given-names>N</given-names></name><name><surname>Kuwabara</surname><given-names>A</given-names></name><name><surname>Fukumura</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>I</given-names></name></person-group>. <article-title>Involvement of circulating interleukin⊟6 and its receptor in the development of euthyroid sick syndrome in patients with acute myocardial infarction</article-title>. <source>Eur J Endocrinol</source> <year>2000</year>; <volume>143</volume>(<issue>2</issue>): <fpage>179</fpage>–<lpage>184</lpage>.</citation></ref>
<ref id="bibr30-1741826711416045"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karga</surname><given-names>H</given-names></name><name><surname>Papaioannou</surname><given-names>P</given-names></name><name><surname>Venetsanou</surname><given-names>K</given-names></name><name><surname>Papandroulaki</surname><given-names>F</given-names></name><name><surname>Karaloizos</surname><given-names>L</given-names></name><name><surname>Papaioannou</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>The role of cytokines and cortisol in the non-thyroidal illness syndrome following acute myocardial infarction</article-title>. <source>Eur J Endocrinol</source> <year>2000</year>; <volume>142</volume>(<issue>3</issue>): <fpage>236</fpage>–<lpage>242</lpage>.</citation></ref>
<ref id="bibr31-1741826711416045"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parle</surname><given-names>JV</given-names></name><name><surname>Maisonneuve</surname><given-names>P</given-names></name><name><surname>Sheppard</surname><given-names>MC</given-names></name><name><surname>Boyle</surname><given-names>P</given-names></name><name><surname>Franklyn</surname><given-names>JA</given-names></name></person-group>. <article-title>Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study</article-title>. <source>Lancet</source> <year>2001</year>; <volume>358</volume>(<issue>9285</issue>): <fpage>861</fpage>–<lpage>865</lpage>.</citation></ref>
<ref id="bibr32-1741826711416045"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>GR</given-names></name><name><surname>Soutar</surname><given-names>AK</given-names></name><name><surname>Spengel</surname><given-names>FA</given-names></name><name><surname>Jadhav</surname><given-names>A</given-names></name><name><surname>Gavigan</surname><given-names>SJ</given-names></name><name><surname>Myant</surname><given-names>NB</given-names></name></person-group>. <article-title>Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1981</year>; <volume>78</volume>(<issue>4</issue>): <fpage>2591</fpage>–<lpage>2595</lpage>.</citation></ref>
<ref id="bibr33-1741826711416045"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volzke</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>DM</given-names></name><name><surname>Spielhagen</surname><given-names>T</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Obst</surname><given-names>A</given-names></name><name><surname>Ewert</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Are serum thyrotropin levels within the reference range associated with endothelial function?</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>(<issue>2</issue>): <fpage>217</fpage>–<lpage>224</lpage>.</citation></ref>
<ref id="bibr34-1741826711416045"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarvisalo</surname><given-names>MJ</given-names></name><name><surname>Harmoinen</surname><given-names>A</given-names></name><name><surname>Hakanen</surname><given-names>M</given-names></name><name><surname>Paakkunainen</surname><given-names>U</given-names></name><name><surname>Viikari</surname><given-names>J</given-names></name><name><surname>Hartiala</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Elevated serum C-reactive protein levels and early arterial changes in healthy children</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2002</year>; <volume>22</volume>(<issue>8</issue>): <fpage>1323</fpage>–<lpage>1328</lpage>.</citation></ref>
<ref id="bibr35-1741826711416045"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dardano</surname><given-names>A</given-names></name><name><surname>Ghiadoni</surname><given-names>L</given-names></name><name><surname>Plantinga</surname><given-names>Y</given-names></name><name><surname>Caraccio</surname><given-names>N</given-names></name><name><surname>Bemi</surname><given-names>A</given-names></name><name><surname>Duranti</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma</article-title>. <source>J Clin Endocrinol Metab</source> <year>2006</year>; <volume>91</volume>(<issue>10</issue>): <fpage>4175</fpage>–<lpage>4178</lpage>.</citation></ref>
<ref id="bibr36-1741826711416045"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>R</given-names></name><name><surname>Apuzzi</surname><given-names>V</given-names></name><name><surname>Bosso</surname><given-names>G</given-names></name><name><surname>D'Anna</surname><given-names>C</given-names></name><name><surname>De</surname><given-names>SA</given-names></name><name><surname>Pirozzi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Recombinant human thyrotropin enhances endothelial-mediated vasodilation of conduit arteries</article-title>. <source>J Clin Endocrinol Metab</source> <year>2009</year>; <volume>94</volume>(<issue>3</issue>): <fpage>1012</fpage>–<lpage>1016</lpage>.</citation></ref>
<ref id="bibr37-1741826711416045"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westerink</surname><given-names>J</given-names></name><name><surname>van der Graaf</surname><given-names>Y</given-names></name><name><surname>Faber</surname><given-names>DR</given-names></name><name><surname>Visseren</surname><given-names>FL</given-names></name><name><surname>SMART study group</surname></name></person-group>. <article-title>The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease</article-title>. <source>Eur J Clin Invest</source> <year>2011</year>; <volume>41</volume>(<issue>2</issue>): <fpage>159</fpage>–<lpage>166</lpage>.</citation></ref>
<ref id="bibr38-1741826711416045"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nannipieri</surname><given-names>M</given-names></name><name><surname>Cecchetti</surname><given-names>F</given-names></name><name><surname>Anselmino</surname><given-names>M</given-names></name><name><surname>Camastra</surname><given-names>S</given-names></name><name><surname>Niccolini</surname><given-names>P</given-names></name><name><surname>Lamacchia</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and/or type 2 diabetes: effects of weight loss</article-title>. <source>Int J Obes (Lond)</source> <year>2009</year>; <volume>33</volume>(<issue>9</issue>): <fpage>1001</fpage>–<lpage>1006</lpage>.</citation></ref>
<ref id="bibr39-1741826711416045"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Hawken</surname><given-names>S</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><name><surname>Bautista</surname><given-names>L</given-names></name><name><surname>Franzosi</surname><given-names>MG</given-names></name><name><surname>Commerford</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study</article-title>. <source>Lancet</source> <year>2005</year>; <volume>366</volume>(<issue>9497</issue>): <fpage>1640</fpage>–<lpage>1649</lpage>.</citation></ref>
<ref id="bibr40-1741826711416045"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>DR</given-names></name><name><surname>van der Graaf</surname><given-names>Y</given-names></name><name><surname>Westerink</surname><given-names>J</given-names></name><name><surname>Visseren</surname><given-names>FL</given-names></name></person-group>. <article-title>Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases</article-title>. <source>Atherosclerosis</source> <year>2010</year>; <volume>212</volume>(<issue>1</issue>): <fpage>274</fpage>–<lpage>280</lpage>.</citation></ref>
<ref id="bibr41-1741826711416045"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Barnett</surname><given-names>JP</given-names></name></person-group>. <article-title>Metabolic and health complications of obesity</article-title>. <source>Dis Mon</source> <year>1990</year>; <volume>36</volume>(<issue>12</issue>): <fpage>641</fpage>–<lpage>731</lpage>.</citation></ref>
<ref id="bibr42-1741826711416045"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>HO</given-names></name><name><surname>Chaker</surname><given-names>H</given-names></name><name><surname>Leaming</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Brechtel</surname><given-names>G</given-names></name><name><surname>Baron</surname><given-names>AD</given-names></name></person-group>. <article-title>Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance</article-title>. <source>J Clin Invest</source> <year>1996</year>; <volume>97</volume>(<issue>11</issue>): <fpage>2601</fpage>–<lpage>2610</lpage>.</citation></ref>
</ref-list>
</back>
</article>